---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-070291"
form_type: "8-K"
ticker: "OLMA"
cik: "0001750284"
company_name: "Olema Pharmaceuticals, Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T16:55:09.967167+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Olema Q1 2025: $392.7M cash, net loss $30.4M; palazestrant combo mPFS 13.8 months

## Summary
- Cash, cash equivalents, and marketable securities of $392.7M at March 31, 2025; net loss $30.4M.
- Updated mPFS from Phase 1b/2: 13.8 months (all patients) and 13.1 months (prior CDK4/6i) for palazestrant+ribociclib.
- Phase 3 OPERA-01 top-line data expected in 2026; OPERA-02 in frontline breast cancer to start in 2025.
- GAAP R&D expenses $30.6M in Q1 2025, up from $29.9M; non-GAAP R&D $27.3M excluding stock comp.
- OP-3136 Phase 1 trial enrollment ongoing; preclinical data at AACR showed activity in ovarian, NSCLC, prostate.

## SEC filing metadata
- accession: 0000950170-25-070291
- form_type: 8-K
- ticker: OLMA
- cik: 0001750284
- company_name: Olema Pharmaceuticals, Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750284/000095017025070291/0000950170-25-070291-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750284/000095017025070291/olma-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-070291
- JSON: https://secwatch.observer/filing/0000950170-25-070291.json
- Plain text: https://secwatch.observer/filing/0000950170-25-070291.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.